In a recently published study, researchers from the Max Planck Institute for Dynamics and Self-Organization in Germany, the University of Cologne, and the University of Washington found that a carefully designed mixtureRead More…
AstraZeneca recently announced that the European Commission (EC) has approved its long-acting antibody therapy Evusheld (tesaglizumab in combination with cilgravizumab, formerly AZD7442) for the treatment of adults and adolescents with severe COVID-19Read More…
Since the first therapeutic antibody Muromonab-CD3 was approved in 1986, more than 100 antibodies have been approved for marketing. Based on their properties, antibodies can be divided into four categories: mouse antibodies,Read More…
The latest update— Cases of COVID-19 in the U.S. at a Glance on April 3, 2020, which include both confirmed and presumptive positive cases of COVID-19 reported to CDC or tested atRead More…
The path to finding a therapeutic antibody that leads to significant medical improvements is often complicated, long, and costly. Many criteria have to be taken into account in order to begin theRead More…
Following the 2018 Nobel Prize for Medicine, global attention is now more than ever turned toward the promise of immunotherapy in oncology. According to a recent study published in the international journalRead More…
A mix of two monoclonal antibodies against HIV tamped down virus levels in patients not taking antiretroviral medication, according to the results of two early-stage clinical trials reported in nature. After several infusionsRead More…
It is well known that the immune system can recognize and remove cancerous cells under normal conditions, but tumor cells will inhibit the immune system in the tumor development process, through differentRead More…
A few days ago, Genentech, a Roche Group member, announced that the US FDA approved Rituxan® (rituximab) for the treatment of moderate to severe pemphigus vulgaris (PV). It is worth mentioning thatRead More…
Checkpoint inhibitor drugs, those that pull the brakes off the immune system, can cause dramatic improvements in cancer patients, but the benefits are far from universal. In the case of atezolizumab (Tecentriq),Read More…